Documentos relacionados

1. Training the next generation of pharmacometric modelers: a multisector perspective.
2. Low-dimensional neural ODEs and their application in pharmacokinetics.
3. Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy.
4. The Finite Absorption Time (FAT) concept en route to PBPK modeling and pharmacometrics.
5. Application of physiologically based pharmacokinetic models for therapeutic proteins and other novel modalities.
6. Machine Learning Models for Human <i>In Vivo</i> Pharmacokinetic Parameters with In-House Validation.
7. Assessment of the nlmixr R package for population pharmacokinetic modeling: A metformin case study.
8. Development of a genetic algorithm and NONMEM workbench for automating and improving population pharmacokinetic/pharmacodynamic model selection.
9. Determination of the Number of Tissue Groups of Kinetically Distinct Transit Time in Whole-Body Physiologically Based Pharmacokinetic (PBPK) Models I: Theoretical Consideration of Bottom-Up Approach of Lumping Tissues in Whole-Body PBPK.
10. [Advantages of population pharmacokinetics and its application in the field of traditional Chinese medicine].